DOI: 10.1093/ofid/ofae645 ISSN: 2328-8957
A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey
Jihad Slim, Paul Bellafiore, Barbara Tempalski, Corey Rosmarin-DeStefano, Kevin Leyden, Juan Torres, Sheena Duprey, Emily LevaggiAbstract
In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.